Work on Indiana University Health’s $4.3 billion downtown hospital campus, one of the most expensive construction projects in Indiana history, is set to be finished in late 2027.
The Roche drug is a once-daily pill, compared to Lilly’s tirzepatide, sold under the brand names Mounjaro (for diabetes) and Zepbound (for obesity), which is a once-weekly shot.
Just three years ago, Indianapolis-based Innovation Associates had huge hopes for growth here. But instead of growing, the company is now shrinking. Last week, the company quietly laid off 11 people in the Indy office and 60 people in other markets.
The expansion plan includes construction of a 100,000-square-foot building on its corporate campus and the addition of 100 jobs.
Duke Energy Indiana, the state’s largest electric utility, in April filed a request with state regulators for permission to raise rates by about 16% over two years.
The Labor Department filed a complaint this week in U.S. District Court against the owner of eight Indianapolis-area health care services companies, saying an estimated 700 employees might have been shortchanged by his practices.
The company had debt of $5.7 billion as of March 31 and has been under pressure from Wall Street to reduce it.
The study followed a group of testicular cancer survivors for an average of 14 years, revealing that 78% experience significant difficulties in everyday listening situations.
Massachusetts-based Morphic Holding Inc. is a nine-year old, publicly traded company that is developing a class of drugs known as oral integrin therapies to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Dr. Greg Hardin, an orthopedic surgeon who specializes in sports medicine, claims that Franciscan Alliance engaged in conduct harmful to his practice over the course of several years.
Community Health Network’s announcement this month that it plans to open a $335 million campus near U.S. 31 and 196th Street in Westfield marks the latest entry into the crowded Hamilton County hospital market.
The Indianapolis-based drugmaker said Thursday it was taking legal action against at least six additional medical spas and weight loss centers that it claimed are selling counterfeit and compounded versions of tirzepatide, the active ingredient in Lilly’s diabetes treatment Mounjaro and weight-loss treatment Zepbound.
Officials with IU Health gave what they called a “summer update” on Wednesday and sounded optimistic about the project, one of the most expensive in Indiana history.
At issue is whether a drug developed by Point Biopharma, based in Indianapolis, infringed on a patent issued in 2020 and assigned to Purdue Research Foundation.
Ascension, the largest Catholic health system in the United States, was hit May 8 by a cyberattack that hindered computer access across the system and affected patient care.
The move comes a year after the Indiana General Assembly passed a law banning noncompete clauses in new contracts for physicians practicing primary care. IU Health said it decided to extend the same benefit to physicians who are currently employed.
The gift, announced Tuesday morning, is from Indianapolis philanthropist and Butler University alumna Marianne Glick and her spouse, Mike Woods.
Lilly officials have said they are “incredibly confident” in the drug’s potential and the fact that it “offers very meaningful benefits to people with early symptomatic Alzheimer’s disease.”
Starting July 1, any health care entity or private equity firm that is planning a merger or acquisition in Indiana—where the assets of at least one of the parties is $10 million or more—must notify the state attorney general at least 90 days in advance.
Longtime business partners Robert Laikin and Larry Paulson, who made their fortunes in the cellphone industry, are turning their sights to manufacturing high-density batteries for industrial uses.
